JP2005533086A - 心臓血管疾患に関連する、分泌ポリペプチド種 - Google Patents

心臓血管疾患に関連する、分泌ポリペプチド種 Download PDF

Info

Publication number
JP2005533086A
JP2005533086A JP2004518589A JP2004518589A JP2005533086A JP 2005533086 A JP2005533086 A JP 2005533086A JP 2004518589 A JP2004518589 A JP 2004518589A JP 2004518589 A JP2004518589 A JP 2004518589A JP 2005533086 A JP2005533086 A JP 2005533086A
Authority
JP
Japan
Prior art keywords
cpp
polypeptide
protein
seq
cardiovascular disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004518589A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533086A5 (enExample
Inventor
リディ・ブーゲルレ
カトリーヌ・ジャンドゥナン
ブルーノ・パルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genova Ltd
Original Assignee
Genova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genova Ltd filed Critical Genova Ltd
Publication of JP2005533086A publication Critical patent/JP2005533086A/ja
Publication of JP2005533086A5 publication Critical patent/JP2005533086A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2004518589A 2002-07-08 2003-06-26 心臓血管疾患に関連する、分泌ポリペプチド種 Pending JP2005533086A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39457602P 2002-07-08 2002-07-08
US43866403P 2003-01-07 2003-01-07
PCT/EP2003/006766 WO2004005931A1 (en) 2002-07-08 2003-06-26 Secreted polypeptide species associated with cardiovascular disorders

Publications (2)

Publication Number Publication Date
JP2005533086A true JP2005533086A (ja) 2005-11-04
JP2005533086A5 JP2005533086A5 (enExample) 2006-08-10

Family

ID=30118429

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004518589A Pending JP2005533086A (ja) 2002-07-08 2003-06-26 心臓血管疾患に関連する、分泌ポリペプチド種

Country Status (5)

Country Link
US (1) US20070009955A1 (enExample)
EP (1) EP1521968A1 (enExample)
JP (1) JP2005533086A (enExample)
AU (1) AU2003249883A1 (enExample)
WO (1) WO2004005931A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069453A1 (ja) * 2005-12-14 2007-06-21 Eisai R & D Management Co., Ltd. 心電図ｑｔ時間延長作用の評価法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1723432A1 (en) 2004-02-05 2006-11-22 Medtronic, Inc. Methods and apparatus for identifying patients at risk for life threatening arrhythmias
US7608458B2 (en) 2004-02-05 2009-10-27 Medtronic, Inc. Identifying patients at risk for life threatening arrhythmias
AU2005253081B2 (en) * 2004-06-03 2011-11-24 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for peripheral artery disease
US8335652B2 (en) 2004-06-23 2012-12-18 Yougene Corp. Self-improving identification method
US8027791B2 (en) 2004-06-23 2011-09-27 Medtronic, Inc. Self-improving classification system
EP2405271A1 (en) * 2010-07-06 2012-01-11 Bio-Rad Innovations Markers of vulnerability of the atherosclerosis plaque
JP6068347B2 (ja) * 2010-10-20 2017-01-25 ルプレクト−カールズ−ウニベルシタット ハイデルベルク 筋機能を増強させる短ペプチド
US11531010B2 (en) * 2017-07-24 2022-12-20 Shimadzu Corporation Ion suppressor and ion chromatograph
TW202028222A (zh) * 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888742A (en) * 1997-10-28 1999-03-30 Incyte Pharmaceuticals, Inc. Human phospholipid binding proteins
ATE440951T1 (de) * 1997-12-17 2009-09-15 Serono Genetics Inst Sa Verlängerte cdns, die für sekretierte proteine kodieren
DE19915485A1 (de) * 1999-04-07 2000-10-19 Hugo A Katus Therapie der Herzinsuffizienz
ATE378601T1 (de) * 1999-07-04 2007-11-15 Cardiovascular Res Inst Of Maa Diagnostischer test für menschlisches matrix gla- protein und seine verwendung als biomarker
GB0021497D0 (en) * 2000-09-01 2000-10-18 Novartis Res Foundation Compounds and their use

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007069453A1 (ja) * 2005-12-14 2007-06-21 Eisai R & D Management Co., Ltd. 心電図ｑｔ時間延長作用の評価法
US8000781B2 (en) 2005-12-14 2011-08-16 Eisai R&D Management Co., Ltd. Method of evaluating effect of prolonging QT interval in electrocardiogram

Also Published As

Publication number Publication date
AU2003249883A1 (en) 2004-01-23
US20070009955A1 (en) 2007-01-11
EP1521968A1 (en) 2005-04-13
WO2004005931A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
US20070082363A1 (en) Secreted polypeptide species reduced cardiovascular disorders
US20080227125A1 (en) Secreted Polypeptide Species Reduced in Cardiovascular Disorders
JP2005533086A (ja) 心臓血管疾患に関連する、分泌ポリペプチド種
JP2005533086A5 (enExample)
JP2007501605A (ja) 心血管疾患に関連する分泌ポリペプチド種
JP2007513063A (ja) 心臓血管障害に関連する分泌ポリペプチド種
JP2006526578A (ja) 心臓血管障害で減少する分泌ポリペプチド種
WO2006029838A2 (en) Secreted polypeptide species involved in alzheimer’s disease
JP2006523191A (ja) 心臓血管障害に関連する分泌ポリペプチド種
US20070128664A1 (en) Secreted polypeptide species associated with cardiovascular disorders
US20070105169A1 (en) Secreted polypeptide species associated with cardiovascular disorders
US20070098635A1 (en) Secreted polypeptide species associatedwith cardiovascular disorders
JP2007527377A (ja) 心臓血管障害で減少される分泌ポリペプチド種
WO2006005585A2 (en) Secreted polypeptide species differentially expressed during pregnancy
EP1626986A2 (en) Secreted polypeptide species associated with cardiovascular disorders
US20060147447A1 (en) Secreted peptides
CA2512629A1 (en) Secreted polypeptide species (fragments from chitotriosidase) reduced in cardiovascular disorders
EP1641821A2 (en) Human secreted proteins
WO2004005331A2 (en) Peptides derived from pep133 (g1p3, 6-16)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090630

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100112